Key facts
- Nula Therapeutics’s last known valuation is $34.0M (Mar 2026).
- It has raised $7.4M across 1 recorded rounds; the latest was Early Stage VC ($7.4M) in Feb 2026.
- Notable investors include GIMIC Ventures.
- Nula Therapeutics has filed 1 Form D with the SEC, most recently Mar 2026 ($7.4M sold to 7 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Nula Therapeutics
Funding rounds
1 roundsAbout Nula Therapeutics
Operator of a biopharmaceutical research company intended for developing small-molecule therapeutics. The company is developing therapeutics by targeting the nuclear envelope to restore healthy gene expression and cell function to treat metabolic dysfunction, neurodegenerative diseases, cancer, and other age-related disorders, enabling patients to improve long-term health and resilience.
- Sector
- Healthcare
- HQ
- FL
- Website
- nulatx.com/
- Ownership
- Privately Held (backing)
Nula Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nula Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nula Therapeutics in its N-PORT filings yet. We sweep new filings monthly.